http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Rallybio to Discontinue Development of RLYB212 for Prevention of FNAIT
-
Rallybio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
-
Rallybio to Present at the TD Cowen 45th Annual Health Care Conference
-
Rallybio Corporation (RLYB) Announces Initiation of Dosing in RLYB212 Phase 2 Clinical Trial
-
Rallybio Announces Initiation of Dosing in RLYB212 Phase 2 Clinical Trial
-
Rallybio Highlights 2024 Accomplishments and Anticipated Milestones for 2025
-
Rallybio Announces Promising RLYB212 and RLYB332 Preclinical Data at the 66th American Society of Hematology Annual Meeting
-
Rallybio to Initiate RLYB116 Confirmatory Clinical PK/PD Study in Second Quarter 2025
-
Rallybio Corporation (RLYB) Announces Publication of Target-Mediated Drug Disposition Modeling and Simulations Informing the RLYB212 Dosing Regimen in Pregnant Women
-
Rallybio Announces Publication of Target-Mediated Drug Disposition Modeling and Simulations Informing the RLYB212 Dosing Regimen in Pregnant Women
-
Rallybio to Present at the 2024 Evercore ISI HealthCONx Conference
-
Rallybio to Provide Update on RLYB116 Program, an Innovative Subcutaneously Injected C5 Inhibitor
-
Rallybio Announces Initiation of Phase 2 Clinical Trial of RLYB212
-
Rallybio Reports Third Quarter 2024 Financial Results and Provides Business Updates
-
Rallybio Corporation (RLYB) Announces Approval of Clinical Trial Applications for Phase 2 Trial of RLYB212
-
Rallybio Announces Approval of Clinical Trial Applications for Phase 2 Trial of RLYB212 in Pregnant Women at Higher Risk of Alloimmunization and FNAIT
-
Data Demonstrating ENPP1 Inhibition as a Therapeutic Approach for Later-onset Hypophosphatasia Presented at the American Society for Bone and Mineral Research 2024 Annual Meeting
-
Rallybio Corporation (RLYB) to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations
-
Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the American Society of Human Genetics 2024 Annual Meeting
-
Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the NORD Breakthrough Summit
-
Fierce Names Rallybio to the 2024 Fierce 50 List as an Innovation Honoree
-
Rallybio Corporation (RLYB) Announces Publication of RLYB212 Phase 1 Proof-of-Concept Study Results
-
Rallybio Announces Publication of RLYB212 Phase 1 Proof-of-Concept Study Results in Thrombosis and Haemostasis
-
Rallybio to Present at Upcoming Investor Conferences
-
Rallybio Reports Second Quarter 2024 Financial Results and Provides Business Updates
-
Rallybio to Present at the 2024 Jones Healthcare Seaside Summit
-
Rallybio Announces Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations
-
Rallybio Reports First Quarter 2024 Financial Results and Provides Business Updates
-
Rallybio to Present at the 2024 Citizens JMP Life Sciences Conference
-
FNAIT Systematic Literature Review and Meta-Analysis Presented at the Academy of Managed Care Pharmacy 2024 Annual Meeting
-
Rallybio Corporation (RLYB) Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia
-
Rallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
-
Rallybio Announces FNAIT Systematic Literature Review to be Presented at the AMCP 2024 Annual Meeting
-
Rallybio Reports Fourth Quarter and Full Year 2023 Financial Results
-
Rallybio to Present at the TD Cowen 44th Annual Health Care Conference
-
Rallybio Corporation (RLYB) Announces Portfolio Prioritization and Provides Corporate Update
-
Rallybio Announces Portfolio Prioritization and Provides Corporate Update
-
Rallybio Corporation (RLYB) Highlights Portfolio Advances and Outlines Expected Milestones in 2024
-
Rallybio Highlights Portfolio Advances and Outlines Expected Milestones in 2024
-
Rallybio (RLYB) Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5
-
Rallybio Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5
-
Rallybio Presents Natural History Study for Fetal and Neonatal Alloimmune Thrombocytopenia at the 65th American Society of Hematology Annual Meeting
-
Rallybio Corporation (RLYB) Announces Preliminary Multiple Dose Data from the Completed Phase 1 Safety and Pharmacokinetics Study for RLYB212
-
Rallybio Announces Preliminary Multiple Dose Data from the Completed Phase 1 Safety and Pharmacokinetics Study for RLYB212, an Anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal
-
Rallybio Reports Third Quarter 2023 Financial Results and Provides Business Updates
-
Rallybio to Present at Upcoming Investor Conferences in November
-
Rallybio Announces Acceptance of FNAIT Natural History Study Abstract for Presentation at the 65th American Society of Hematology Annual Meeting
-
Rallybio to Present at the JonesTrading 2023 Healthcare Summit
-
Rallybio Corporation (RLYB) Presents Phase 1 Single Ascending Dose Data for RLYB116
-
Rallybio Presents Phase 1 Single Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5
